|
Biological Activity:
Selective agonist for retinoid X receptors (RXR); An oral antineoplastic agent indicated for cutaneous T cell lymphoma (CTCL).
References: online
R Gniadecki et al. The optimal use of bexarotene in cutaneous T-cell lymphoma. Br. J. Dermatol. 2007, 157(3), 433–440. [online]
KH Dragnev et al. A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer. Clin Cancer Res. 2007, 13(6), 1794-800. [online]
Chemical Name: 4-[1-(3,5,5,8,8-pentamethyltetralin-2-yl)ethenyl]benzoic acid
|